<DOC>
	<DOCNO>NCT00914771</DOCNO>
	<brief_summary>This study aim demonstrate non-inferiority two dos H5N1 influenza antigen non-elderly elderly adult subject order submit extension application lower dose Focetria .</brief_summary>
	<brief_title>Safety Immunogenicity Two Doses , Administered Three Weeks Apart , Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses H5N1 Influenza Antigen , Non-elderly Adult Elderly Subjects</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Influenza Birds</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Males females 18 yrs age day enrollment . Individuals good health determine medical history , physical examination clinical judgment investigator Documented consent obtain nature study explain accord local regulatory requirement Individuals able comply study procedure available clinic visit schedule study Individuals able comprehend follow require study procedure whole period study consent retention subject 's serum sample study completion . Individuals behavioral cognitive impairment psychiatric disease , opinion investigator , may interfere subject 's ability participate study Individuals history illness , opinion investigator , might interfere result study pose additional risk subject due participation study Individuals influenza vaccine document suspected influenza disease within 6 month prior Day 1 . Laboratoryconfirmed suspected influenza disease within 6 month prior Visit 1 . `` Laboratoryconfirmed '' include : 1 . Positive serology result 2 . Positive viral culture 3 . Positive rapid antigen test 4 . `` Suspected '' influenza disease include : subject influenzalike illness within past 6 month household/intimate contact `` laboratoryconfirmed '' influenza disease Individuals experience acute disease infection require systemic antibiotic antiviral therapy within 6 day vaccination ( chronic antibiotic therapy urinary tract prophylaxis acceptable ) History anaphylaxis , serious vaccine reaction , hypersensitivity influenza viral protein , excipients , egg ( include ovalbumin ) , chicken protein . History serious disease , : . Medically significant cancer ( except benign localize skin cancer , cancer remission ≥10 year localized prostate cancer clinically stable 2 year without treatment ) b. autoimmune disease ( include rheumatoid arthritis ) except Hashimoto 's thyroiditis clinically stable ≥ 5 year ; c. diabetes mellitus type I ; d. poorly control diabetes mellitus type II ; e. diabetes relate genetic defects/syndromes , disease exocrine pancreas , infection ; f. advance arteriosclerotic disease ; g. severe chronic obstructive pulmonary disease ( COPD ) , i.e . GOLD stag 3 4 ; h. acute progressive hepatic disease ; i. acute progressive renal disease ; j. medically significant congestive heart failure ; k. history underlying medical condition major congenital abnormality require surgery , chronic treatment , associate developmental delay ( e.g. , Down 's syndrome ) Known suspect impairment/alteration immune function , include : 1 . Receipt immunosuppressive therapy oral systemic corticosteroid , ( use inhale , intranasal , topical corticosteroid allow ) cancer chemotherapy within 60 day prior Visit 1 2. receipt immunostimulants within 60 day prior Visit 1 3. receipt parenteral immunoglobulin preparation , blood product , and/or plasma derivates within 3 month prior Visit 1 plan full length study 4 . HIV infection HIVrelated disease 5 . Heritable immunodeficiency 6 . Abnormalities splenic thymic function Receipt another vaccine within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior Day 1 plan vaccination Day 43 . Seasonal influenza vaccination allow 3 week last study vaccination ( blood sample serology Day 43 ) Experienced body temperature ≥38.0°C ( 100.4°F ) within 3 day prior study vaccination . Use antipyretic/analgesic medication within 24 hour study vaccination Receipt another investigational agent within 30 day prior enrollment study completion safety followup period another study , whichever longer , prior enrollment unwilling refuse participation another clinical study end study Pregnant breastfeed female Any positive indeterminate pregnancy test If female , childbearing potential , use `` acceptable contraceptive method '' least 2 month prior study entry 1 . Of childbearing potential defined status post onset menarche surgically sterile 2 . Acceptable birth control method define one following : i. Hormonal contraceptive ( oral , injection , transdermal patch , implant , cervical ring ) ii . Barrier ( condom spermicide diaphragm spermicide ) every time intercourse iii . Intrauterine device ( IUD ) iv . Monogamous relationship vasectomize partner . Partner must vasectomize least six month prior subject 's study entry If female childbearing potential , refusal use `` acceptable contraceptive method '' study include day 43 . If female childbearing potential , refusal submit pregnancy test prior study vaccination Research staff directly involve clinical study family member household member research staff . Research staff individual direct indirect contact study subject , study site personnel access study document contain subject information . This would include receptionist , person schedule appointment make screen call , regulatory specialist , laboratory technician , etc . Elective surgery hospitalization plan period study participation . BMI &gt; 35Kg/m2 BMI obese high muscle mass Individuals history substance alcohol abuse within past 2 year opinion Investigator might interfere safety subject evaluation study objective . Any condition , opinion Investigator , might interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Pandemic Influenza</keyword>
	<keyword>H5N1</keyword>
	<keyword>Adults Elderly</keyword>
	<keyword>antigen dose</keyword>
</DOC>